Orion Infusions (DHA:ORIONINFU) Cyclically Adjusted Revenue per Share: BDT44.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
80 GF Score
Price BDT288.90
GF Value BDT315.62
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Cyclically Adjusted Revenue per Share?

Orion Infusions DHA:ORIONINFU -0.48% 80 Cyclically Adjusted Revenue per Share is BDT44.28 as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 80/100 and a GF Value™ of BDT315.62 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orion Infusions's adjusted revenue per share for the three months ended in Mar. 2026 was BDT4.080. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is BDT44.28 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orion Infusions's average Cyclically Adjusted Revenue Growth Rate was -0.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Orion Infusions was 1.80% per year. The lowest was 1.80% per year. And the median was 1.80% per year.

As of today (2026-07-24), Orion Infusions's current stock price is BDT288.90. Orion Infusions's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was BDT44.28. Orion Infusions's Cyclically Adjusted PS Ratio of today is 6.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orion Infusions was 23.02. The lowest was 2.07. And the median was 8.26.


Orion Infusions  (DHA:ORIONINFU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orion Infusions's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=288.90/44.28
=6.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orion Infusions was 23.02. The lowest was 2.07. And the median was 8.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orion Infusions Cyclically Adjusted Revenue per Share Related Terms


Orion Infusions Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Orion Infusions's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions Cyclically Adjusted Revenue per Share Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 42.18 43.24 44.37 44.47

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.38 44.47 44.35 44.17 44.28

DHA:ORIONINFU vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orion Infusions's Cyclically Adjusted PS Ratio falls into.


DHA:ORIONINFU
80GF Score
Orion Infusions Ltd DHA:ORIONINFU
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orion Infusions's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.08/330.2130*330.2130
=4.080

Current CPI (Mar. 2026) = 330.2130.

Orion Infusions Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 9.779 241.018 13.398
201609 9.181 241.428 12.557
201612 7.771 241.432 10.629
201703 7.487 243.801 10.141
201706 8.978 244.955 12.103
201709 8.324 246.819 11.136
201712 8.841 246.524 11.842
201803 5.999 249.554 7.938
201806 13.802 251.989 18.087
201809 10.280 252.439 13.447
201812 9.400 251.233 12.355
201903 9.540 254.202 12.393
201906 10.509 256.143 13.548
201909 12.186 256.759 15.672
201912 9.818 256.974 12.616
202003 6.555 258.115 8.386
202006 7.766 257.797 9.947
202009 7.902 260.280 10.025
202012 8.016 260.474 10.162
202103 8.267 264.877 10.306
202106 11.473 271.696 13.944
202109 11.782 274.310 14.183
202112 9.214 278.802 10.913
202203 8.922 287.504 10.247
202206 10.679 296.311 11.901
202209 11.048 296.808 12.291
202212 9.791 296.797 10.893
202303 8.915 301.836 9.753
202306 9.965 305.109 10.785
202309 11.584 307.789 12.428
202312 10.007 306.746 10.773
202403 10.358 312.332 10.951
202406 8.836 314.175 9.287
202409 9.756 315.301 10.217
202412 9.612 315.605 10.057
202503 5.015 319.799 5.178
202506 8.337 322.561 8.535
202509 8.117 324.800 8.252
202512 11.274 324.054 11.488
202603 4.080 330.213 4.080

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of BDT44.28 mean?
Orion Infusions (DHA:ORIONINFU) has a Cyclically Adjusted Revenue per Share of BDT44.28 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' Cyclically Adjusted Revenue per Share too high?
Orion Infusions' current Cyclically Adjusted Revenue per Share is BDT44.28. Overall, Orion Infusions has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Orion Infusions' Cyclically Adjusted Revenue per Share of BDT44.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orion Infusions and its competitors. Orion Infusions's current Cyclically Adjusted Revenue per Share is BDT44.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT315.62, compared to a current price of BDT288.90 — trading 8.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is BDT44.28. Orion Infusions' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Cyclically Adjusted Revenue per Share is BDT44.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT288.90 is trading 8.5% below its estimated GF Value™ of BDT315.62. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • Cyclically Adjusted Revenue per Share: BDT44.28
  • GF Value™: BDT315.62 vs. price of BDT288.90 (8.5% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
80GF Score

Get the complete analysis for DHA:ORIONINFU

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT288.90
Price
BDT315.62
GF Value